LAMIVUDINE AND DOLUTEGRAVIR

DRUG3 trials

Sponsors

Gilead Sciences Inc., Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le Sida, ANRS Maladies Infectieuses Emergentes, Ospedale Pediatrico Bambino Gesu

Conditions

HIVHIV-1 Infectionperinatally HIV infection

Phase 3

MODULO trial: doravirine/lamivudine (DOR/3TC) as a maintenance ART in comparison with dolutegravir/lamivudine (DTG/3TC) in PLWH successfully treated with three-drug regimens at inclusion

RecruitingCTIS2024-515793-27-01

Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le Sida, ANRS Maladies Infectieuses EmergentesHIV

Start: 2025-04-30Target: 408Updated: 2025-10-24

A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care

Active, not recruitingCTIS2024-514047-28-00

Gilead Sciences Inc.HIV-1 Infection

Start: 2025-01-27Target: 98Updated: 2025-09-12

The Italian Cohort (ITACO) and the Analytical Antiretroviral Treatment Interruption Italian Cohort (ITACO-ATI) study guided by molecular HIV-1 reservoir profiling

RecruitingCTIS2024-518694-33-00

Ospedale Pediatrico Bambino Gesuperinatally HIV infection

Start: 2023-08-08Target: 61Updated: 2025-07-24